A Src SH2 selective binding compound inhibits osteoclast-mediated resorption

Chemistry and Biology

Volumn 7, Issue 3, 2000, Pages 225-235

  Violette, Shelia M ^a   Shakespeare, William C ^a   Bartlett, Catherine ^a   Guan, Wei ^a   Smith, Jeremy A ^a   Rickles, Richard J ^a   Bohacek, Regine S ^a   Holt, Dennis A ^a   Baron, Roland ^b   Sawyer, Tomi K ^a  

^a ARIAD PHARMACEUTICALS INC   (United States)

^b SANOFI   (France)

Author keywords

Osteoclast; Resorption; SH2 domain; Src; Tyrosine kinase

Indexed keywords

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 17344380187     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(00)00090-9     Document Type: Article

References (47)

1. Brown M.T., Cooper J.A. Regulation, substrates and functions of Src. Biochim. Biophys. Acta. 1287:1996;121-149.
2. Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13:1997;513-609.
3. Parsons J.T., Weber M.J. Genetics of src: structure and functional organization of a protein tyrosine kinase. Current Topics In Microbiology and Immunology, Volume 147. 1989;79-127 Springer-Verlag, Berlin-Heidelberg.
4. Schwartzberg P. The many faces of Src: multiple functions of a prototypical tyrosine kinase. Oncogene. 17:1998;1463-1468.
5. Klinghoffer R.A., Sachsenmaier C., Cooper J.A., Soriano P. Src family kinases are required for integrin but not PDGFR signal transduction. EMBO J. 18:1999;2459-2471.
6. Lowell C.A., Soriano P. Knockouts of Src-family kinases: stiff bones, wimpy T-cells and bad memories. Genes Dev. 10:1996;1845-1857.
7. Soriano P., Montgomery C., Geske R., Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 64:1991;693-702.
8. c-src expression for osteoclasts to form ruffled borders and to resorb bone in mice. J. Clin. Invest. 90:1992;1622-1627.
9. Lowe C., Yoneda T., Boyce B.F., Chen H., Mundy G.R., Soriano P. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc. Natl. Acad. Sci. USA. 90:1993;4485-4489.
10. c-src in association with intracellular membranes. J. Cell. Biol. 119:1992;1003-1013.
11. Tanaka S., Baron R.et al. c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature. 383:1996;528-531.
12. -/- mutant mice. Genes Dev. 11:1997;2835-2844.
13. c-src tyrosine kinase inhibitor, inhibits osteoclast bone resorption in vitro and hypercalcemia in vivo. J. Clin. Invest. 91:1993;2791-2795.
14. Hall T.J., Schaeublin M., Missbach M. Evidence that c-src is involved in the process of osteoclast bone resorption. Biochem. Biophys. Res. Commun. 199:1994;1237-1244.
15. Blair H.C., Jordan S.E., Peterson T.G., Barnes S. Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats. J. Cell. Biochem. 61:1996;629-637.
16. Missbach M., Susa M.et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone. 24:1999;437-439.
17. Waksman G., Kuriyan J.et al. Crystal structure of the phosphotyrosine recognition domain (SH2) of the v-src tyrosine kinase complexed with tyrosine phosphorylated peptides. Nature. 358:1992;646-653.
18. Superti-Furga G., Courtneidge S.A. Structure-function relationships in Src family and related protein tyrosine kinases. BioEssays. 17:1995;321-330.
19. Hanks S.K., Hunter T. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9:1995;576-596.
20. c-src SH2 domains: a thermodynamic and structural study. Biochemistry. 36:1997;6283.
21. Alligwood K.J., Sternbach D.D.et al. The formation of a covalent complex between a dipeptide ligand and the Src SH2 domain. Bioorg. Med. Chem. Lett. 7:1998;1189-1194.
22. Holt D.A., Veber D.F., Yamashita D.S. Method of antagonizing the human Src SH2 domain for treating bone resorption diseases. PCT Int. Appl. WO9840093. 1998.
23. Shaw E. The selective inactivation of thiol proteases in vitro and in vivo. J. Protein Chem. 3:1984;109-119.
24. Shaw E. Cysteinyl proteinases and their selective inactivation. Adv. Enymol. Relat. Area Mol. Biol. 63:1990;271-347.
25. Rich D.H. Proteinase Inhibitors. 1996;Elsevier, Amsterdam.
26. Otto H.-H., Schirmeister T. Cysteine proteases and their inhibitors. Chem. Rev. 97:1997;171-333.
27. a values. Protein Sci. 6:1997;1910-1919.
28. Gay B., Schoepfer J.et al. Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility. J. Biol. Chem. 274:1999;23311-23315.
29. Lynch B.A., Loiacono K.A., Tiong C.L., Adams S.E., MacNeil I.A. A fluorescence polarization based Src-SH2 binding assay. Anal. Biochem. 247:1997;77-82.
30. Waksman G., Kuriyan J.et al. Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides. Nature. 358:1992;646-653.
31. Songyang Z., Cantley L.C.et al. SH2 domains recognize specific phosphopeptide sequences. Cell. 72:1993;767-778.
32. Rickles R.J., Zoller M.et al. A novel mechanism-based mammalian cell assay for the identification of SH2-domain-specific protein-protein inhibitors. Chem. Biol. 5:1998;529-538.
33. Roche S., Koegl M., Barone M.V., Roussel M.F., Courtneidge S.A. DNA synthesis induced by some but not all growth factors requires Src family protein tyrosine kinases. Mol. Cell. Biol. 15:1995;1102-1109.
34. Hanke J.H., Connelly P.A.et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. J. Biol. Chem. 271:1996;695-701.
35. Schlaepfer D.D., Broome M.A., Hunter T. Fibronectin-stimulated signaling from a focal adhesion kinase-c-Src complex: involvement of the Grb2, p130cas, and Nck adaptor proteins. Mol. Cell. Biol. 17:1997;1702-1713.
36. Kaplan K.B., Swedlow J.R., Morgan D.O., Varmus H.E. c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev. 9:1995;1505-1517.
37. Horton M.A., Taylor M.L., Arnett T.R., Helfrich M.H. Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. Exp. Cell Res. 195:1991;368-375.
38. Dresner-Pollak R., Rosenblatt M. Blockade of osteoclast-mediated bone resorption through occupancy of the integrin receptor: a potential approach to the therapy of osteoporosis. J. Cell Biochem. 56:1994;323-330.
39. Rodan S.B., Rodan G.A. Integrin function in osteoclasts. J. Endocrinol. 154:1997;47-56.
40. Duong L.T., Lakkakorpi P.T., Nakamura I., Machwate M., Nagy R.M., Rodan G.A. PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase. J. Clin. Invest. 102:1998;881-892.
41. Chellaiah M., Fitzgerald C., Filardo E.J., Cheresh D.A., Hruska K.A. Osteopontin activation of c-src in human melanoma cells requires the cytoplasmic domain of the integrin alpha v-subunit. Endocrinology. 137:1996;2432-2440.
42. Lowell C.A., Niwa M., Soriano P., Varmus H.E. Deficiency of the Hck and Src kinases results in extreme levels of extramedullary hematopoiesis. Blood. 87:1996;1780-1792.
43. Stein P.L., Vogel H., Soriano P. Combined deficiencies of Src, Fyn and Yes tyrosine kinases in mutant mice. Genes Dev. 8:1994;1999-2007.
44. Shakespeare W.C., Holt D.A.et al. An efficient synthesis of 4'-phosphonodifluoromethyl-3'-formyl-phenylalanine: incorporation into a peptidomimetic src SH2 ligand. Bioorg. Med. Chem. Lett. 9:1999;3109-3112.
45. Dunnington D., Gowen M. Inhibition of bone resorption by src SH2 domain antagonists. J. Bone Min. Res. 11:1996;398.
46. Suh J.T., Schnettler R.A. 2-3-Hydroxymethyltyrosine and salts thereof for lowering blood pressure. US patent 4. 022:1977;910.
47. Vu C.B., Sawyer T.K.et al. Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70. J. Med. Chem. 42:1999;4088-4098.